FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the “Hearings Panel”) has cancelled the previously scheduled hearing regarding Celularity’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), as the Company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity’s stock will continue to be listed and traded on The Nasdaq Stock Market.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Statement from Paul DelPonte, Executive Director at the National Crime Prevention Council on today’s ruling in Neville et al. v. Snap, Inc. - December 5, 2024
- 2024 China-ASEAN Marathon Begins in Fangchenggang City - December 5, 2024
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages The Toronto-Dominion Bank Investors to Secure Counsel Before Important Deadline in Securities Class Action – TD - December 5, 2024
